Cogent Biosciences, Inc.
COGTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. The $6.03B market capitalization puts COGT squarely in mid-cap range for its industry. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Market Cap
$6.03B
Beta
0.31
P/E (TTM)
—
P/E (Fwd)
-31.37
EPS (TTM)
$-2.15
EPS (Fwd)
$-1.11
ROE
-109.7%
ROA
-43.8%
Cash
$792.3M
Total Debt
$244.3M
Free CF
-$186.1M
52W Change
167.8%
Annual Financials
Cash vs Debt
Where COGT stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, COGT finished 5.51% below its 150-day moving average ($36.69) and 6.15% below its 200-day moving average ($36.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COGT overbought or oversold?
At the August 31, 2026 close, COGT's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $792.3M in cash and $244.3M in debt, COGT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$186.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -109.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Cogent Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, COGT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cogent Biosciences, Inc. and its sector.